2021
Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt
Youssry I, ElGhamrawy M, Seif H, Balsamo L, Pashankar F, Mahrous M, Salama N. Prevalence and risk factors of cognitive impairment in children with sickle cell disease in Egypt. International Journal Of Hematology 2021, 115: 399-405. PMID: 34792734, DOI: 10.1007/s12185-021-03260-1.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh lactate dehydrogenaseCell diseaseCognitive impairmentRisk factorsLactate dehydrogenaseCairo University Children's HospitalOlder ageSickle cell disease patientsUniversity Children's HospitalPossible risk factorsMagnetic resonance angiographyMagnetic resonance imagingHydroxyurea therapyTranscranial DopplerChildren's HospitalDisease patientsUnivariate analysisEarly initiationPatientsResonance angiographyImpaired cognitionResonance imagingIntelligence quotient (IQ) testDisease
2015
Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease
Pashankar FD, Manwani D, Lee MT, Green NS. Hydroxyurea Improves Oxygen Saturation in Children With Sickle Cell Disease. Journal Of Pediatric Hematology/Oncology 2015, 37: 242-243. PMID: 25222060, PMCID: PMC4362807, DOI: 10.1097/mph.0000000000000251.Peer-Reviewed Original Research
2013
Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea. PLOS ONE 2013, 8: e55709. PMID: 23409025, PMCID: PMC3567082, DOI: 10.1371/journal.pone.0055709.Peer-Reviewed Original ResearchConceptsSickle cell diseaseFetal hemoglobin levelsHemoglobin levelsCell diseaseFetal hemoglobinBaseline levelsAdult sickle cell diseasePediatric sickle cell diseaseSubset of childrenPharmacologic therapyHydroxyurea therapyClinical severityPediatric diseasesInduced levelsSignificant associationTherapeutic inductionCandidate single nucleotide polymorphismsDiseaseSingle nucleotide polymorphismsHemoglobinSequence variantsChildrenTherapyBaselineHydroxyurea
2012
Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease
Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar F, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatric Blood & Cancer 2012, 60: 653-658. PMID: 23129068, PMCID: PMC3625668, DOI: 10.1002/pbc.24381.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHU useCell diseaseHematology providersBivariate analysisPediatric sickle cell diseaseBenefits of hydroxyureaMajor therapeutic effectMultivariate logistic regressionLong-term safetyPotential side effectsParental knowledgeBetter parental knowledgeHU usersHydroxyurea useInter-institutional variabilityParents of childrenChildren ages 5Label useSickle genotypeTherapeutic effectClinical careEffective treatmentSide effectsClinical practice